Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.

Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, Kaaks R, Chang-Claude J.

Int J Cancer. 2012 Mar 15;130(6):1401-10. doi: 10.1002/ijc.26157. Epub 2011 Jul 21.

2.

Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.

Xie J, Tworoger SS, Franke AA, Terry KL, Rice MS, Rosner BA, Willett WC, Hankinson SE, Eliassen AH.

Breast Cancer Res Treat. 2013 Jun;139(3):801-9. doi: 10.1007/s10549-013-2586-y. Epub 2013 Jun 13.

3.

Serum enterolactone and prognosis of postmenopausal breast cancer.

Buck K, Vrieling A, Zaineddin AK, Becker S, Hüsing A, Kaaks R, Linseisen J, Flesch-Janys D, Chang-Claude J.

J Clin Oncol. 2011 Oct 1;29(28):3730-8. doi: 10.1200/JCO.2011.34.6478. Epub 2011 Sep 6.

PMID:
21900115
4.

Plasma enterolactone and breast cancer incidence by estrogen receptor status.

Olsen A, Knudsen KE, Thomsen BL, Loft S, Stripp C, Overvad K, Møller S, Tjønneland A.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2084-9.

5.

Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.

Pietinen P, Stumpf K, Männistö S, Kataja V, Uusitupa M, Adlercreutz H.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):339-44.

6.

Circulating enterolactone and risk of breast cancer: a prospective study in New York.

Zeleniuch-Jacquotte A, Adlercreutz H, Shore RE, Koenig KL, Kato I, Arslan AA, Toniolo P.

Br J Cancer. 2004 Jul 5;91(1):99-105.

7.

Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.

Sonestedt E, Borgquist S, Ericson U, Gullberg B, Olsson H, Adlercreutz H, Landberg G, Wirfält E.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3241-51. doi: 10.1158/1055-9965.EPI-08-0393.

8.

Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE.

J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65.

PMID:
15601642
9.
10.
11.

Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.

Kilkkinen A, Virtamo J, Vartiainen E, Sankila R, Virtanen MJ, Adlercreutz H, Pietinen P.

Int J Cancer. 2004 Jan 10;108(2):277-80.

12.

Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis.

Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, Kaaks R, Linseisen J, Obi N, Heinz J, Flesch-Janys D, Chang-Claude J.

Int J Cancer. 2014 Aug 15;135(4):923-33. doi: 10.1002/ijc.28729. Epub 2014 Feb 5.

13.

Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status.

Touillaud MS, Thiébaut AC, Fournier A, Niravong M, Boutron-Ruault MC, Clavel-Chapelon F.

J Natl Cancer Inst. 2007 Mar 21;99(6):475-86.

14.

Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.

Kahán Z, Gardi J, Nyári T, Földesi I, Hajnal-Papp R, Ormándi K, Lázár G, Thurzó L, Schally AV.

Int J Oncol. 2006 Jul;29(1):193-200.

PMID:
16773200
15.

Prediagnostic plasma enterolactone levels and mortality among women with breast cancer.

Olsen A, Christensen J, Knudsen KE, Johnsen NF, Overvad K, Tjønneland A.

Breast Cancer Res Treat. 2011 Aug;128(3):883-9. doi: 10.1007/s10549-011-1397-2. Epub 2011 Feb 22.

PMID:
21340481
16.

Risk factors for hormone receptor-defined breast cancer in postmenopausal women.

Rosenberg LU, Einarsdóttir K, Friman EI, Wedrén S, Dickman PW, Hall P, Magnusson C.

Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2482-8.

17.

Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies.

Suzuki R, Orsini N, Mignone L, Saji S, Wolk A.

Int J Cancer. 2008 Apr 15;122(8):1832-41. Erratum in: Int J Cancer. 2008 Aug 15;123(4):981.

18.

Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.

Suzuki R, Orsini N, Saji S, Key TJ, Wolk A.

Int J Cancer. 2009 Feb 1;124(3):698-712. doi: 10.1002/ijc.23943.

19.

Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.

Vrieling A, Buck K, Kaaks R, Chang-Claude J.

Breast Cancer Res Treat. 2010 Oct;123(3):641-9. doi: 10.1007/s10549-010-1116-4. Epub 2010 Aug 15. Review.

PMID:
20711809
20.

Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.

Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR.

Breast Cancer Res Treat. 2011 Feb;126(1):149-55. doi: 10.1007/s10549-010-1074-x. Epub 2010 Jul 29.

Supplemental Content

Support Center